Member Info for Livedataaccount

What exactly were you expecting to hear?

Two weekly study is in full swing and that data along with the 1a data will be used for the dose expa sion study starting this year (hopefully) leading onto phase 2 h1 2025

Since it's Friday for a bit of fun I've decided Avacta needs a rebrand and a new name.

The new name should be pivotX since most companies have a x these days and Avacta has a habit of pivoting.

Nysize. Majority of posters posting anything negative have been abused on this forum.

Mchurk the avacta die hards, Timster et Al are far far worse than any other.

They have constantly abused anyone who has questioned Avacta.

Touk, I wouldn't read too much into that

Next update it will be something completely different

Interesting that the CEO hasn't made himself available for interviews today.

Every other major event at Avacta in recent times he has done a Vox etc interview.

I'd be weary of Avacta listing on the Nasdaq.

They would spend most of their time fending off investor lawsuits.

Recently

Neil Bell, the Chief Therapeutics Development officer left

Fiona McLaughlin the Chief Scientific officer left.

Chris Coughlin is brought on as temp then assumes a new head of R& D role

The company promised a data rich presentation in December for phase 1a. It was anything but (thank god Chris Coughlin did the talking though).

Simon Bennett is brought in as a deal maker

This is sold to shareholders as a natural evolution as the company enters the "commercial phase". Really? Are Avacta really at the commercialization stage? AVA6000 hasnt started efficay studies yet.

Weeks later the company does a massively leaked fundraise at 50 PENCE

Whatever is going on, its very odd and long term shareholder are being punished right now.

No, watching. An interview with the AIM circus is the last thing Avacta should do.

'' In light of the strong demand received both from existing investors and potential new holders, the Board has decided to increase the size of the Placing from approximately £20 million to £25.7 million.''

So why didn't Avacta accept the extra funds during the last fundraiser which was circa twice the price? Hindsight is obviously a wonderful thing. But couple that with blowing funds on dx. The strategy seems well off.

And dx is not cash generating. 2024 they expect dx to ebitda positive. Ie. Probably losing cash.

But cash geerative in 2025 (allegedly)

Way to go Mr Smith

And a dose expansion removed one month and added the next.

Do Avacta know what they are doing?

A few people mentioned at the time it was very odd to spend a Big chunk of a raise on dx when tx was in need of money.

Avacta die hard fans defended it with the usual conjecture. 'must of been a condition of the raise*. I believe that to be nonsense as avacta now looking to divest with bond ongoing.

Poor poor management from Avacta

Yes, absolutely reckless

A necessary complication? Really? If it was a condition of HCI bond, they wouldn't be trying to flog it with bond ongoing.

Exactly. And funds should not have been wasted on dx companies adding to this mess Avacta have got themselves in.

The format of the trial appears to change quarter on quarter. Obviously these things are subject to change but alongside this raise questions need to be answered

P1 has been going on for knocking on 3 years

I saw that. I just look at it from a timescale perspective. Assuming the dose expansion will take months? When will P2 start?

So what is the dose expansion phase then? I thought the 2 weekly was replacing this?